ArticlePloS one2013
Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 89 citations in OpenAlex.
- Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy.International journal of molecular sciences · 2026Review
- Good manufacturing practice production of an off-the-shelf CD34Cellular and molecular life sciences : CMLS · 2025Article
- Development of Animal Models for Preclinical Safety Studies.Advances in experimental medicine and biology · 2025Review
- Feeder-cell-free system forFrontiers in immunology · 2025Article
- CAR-NK cells derived from cord blood originate mainly from CD56Molecular therapy. Methods & clinical development · 2024Article
- Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach.Journal of extracellular biology · 2024Review
- Article
- In Vivo PET Imaging ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.Frontiers in oncology · 2024Review
- Good manufacturing practice production of CD34Cancer immunology, immunotherapy : CII · 2023Article
- Comparison of cytotoxic potency between freshly cultured and freshly thawed cytokine-induced killer cells from human umbilical cord blood.Cell and tissue banking · 2023Article
- Umbilical cord blood derived cellular therapy: advances in clinical development.Frontiers in oncology · 2023Review
- Characterization of the biological and transcriptomic signatures of natural killer cells derived from cord blood and peripheral blood.American journal of cancer research · 2023Article
- Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy.Frontiers in immunology · 2023Review
- Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?Cancers · 2022Review
- CAR-NK cells for cancer immunotherapy: from bench to bedside.Biomarker research · 2022Review
- IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34Cancer immunology, immunotherapy : CII · 2021Article
- Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.Stem cell research & therapy · 2021Review
- CAR-NK cells: the next wave of cellular therapy for cancer.Clinical & translational immunology · 2021Review
- CD34Oncoimmunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cell-based adoptive immunotherapy is an attractive adjuvant treatment option for patients with acute myeloid leukemia. Recently, we reported a clinical-grade, cytokine-based culture method for the generation of NK cells from umbilical cord blood (UCB) CD34⁺ hematopoietic progenitor cells with high yield, purity and in vitro functionality. The present study was designed to evaluate the in vivo anti-leukemic potential of UCB-NK cells generated with our GMP-compliant culture system in terms of biodistribution, survival and cytolytic activity following adoptive transfer in immunodeficient NOD/SCID/IL2Rg(null) mice. Using single photon emission computed tomography, we first demonstrated active migration of UCB-NK cells to bone marrow, spleen and liver within 24 h after infusion. Analysis of the chemokine receptor expression profile of UCB-NK cells matched in vivo findings. Particularly, a firm proportion of UCB-NK cells functionally expressed CXCR4, what could trigger BM homing in response to its ligand CXCL12. In addition, high expression of CXCR3 and CCR6 supported the capacity of UCB-NK cells to migrate to inflamed tissues via the CXCR3/CXCL10-11 and CCR6/CCL20 axis. Thereafter, we showed that low dose IL-15 mediates efficient survival, expansion and maturation of UCB-NK cells in vivo. Most importantly, we demonstrate that a single UCB-NK cell infusion combined with supportive IL-15 administration efficiently inhibited growth of human leukemia cells implanted in the femur of mice, resulting in significant prolongation of mice survival. These preclinical studies strongly support the therapeutic potential of ex vivo-generated UCB-NK cells in the treatment of myeloid leukemia after immunosuppressive chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.